Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time.
Circ J
; 78(3): 763-6, 2014.
Article
em En
| MEDLINE
| ID: mdl-24451650
ABSTRACT
BACKGROUND:
Prothrombin time (PT) distribution in Japanese nonvalvular atrial fibrillation (NVAF) patients under rivaroxaban therapy remains to be clarified. METHODS ANDRESULTS:
Between May 2012 and July 2013, 115 NVAF patients received rivaroxaban (PT was measured in 94; reagent recombiplastin). In these patients, (1) PT values were distributed widely from patient to patient and from peak to trough, (2) the time-dependence was obscure with sampling at any time in the outpatient clinic, and (3) the incidence of adverse events was too low for analyzing the relation with PT.CONCLUSIONS:
We report the distribution of PT for Japanese NVAF patients under rivaroxaban therapy in real-world clinical practice.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Tempo de Protrombina
/
Fibrilação Atrial
/
Tiofenos
/
Morfolinas
/
Inibidores do Fator Xa
Tipo de estudo:
Clinical_trials
/
Observational_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
Asia
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article